OTCPK:HLTR.F

Stock Analysis Report

Executive Summary

HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.

Risks

  • HLS Therapeutics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has HLS Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-17.1%

HLTR.F

-0.7%

US Healthcare

-0.5%

US Market


1 Year Return

16.7%

HLTR.F

-9.3%

US Healthcare

0.9%

US Market

HLTR.F outperformed the Healthcare industry which returned -9.2% over the past year.

HLTR.F outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

HLTR.FIndustryMarket
7 Day-17.1%-0.7%-0.5%
30 Day-17.1%1.6%4.8%
90 Day-5.1%-0.6%2.3%
1 Year18.1%16.7%-7.9%-9.3%3.1%0.9%
3 Yearn/a29.5%24.3%45.5%36.0%
5 Yearn/a65.6%55.8%62.5%44.7%

Price Volatility Vs. Market

How volatile is HLS Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is HLS Therapeutics undervalued based on future cash flows and its price relative to the stock market?

1.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

HLS Therapeutics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

HLS Therapeutics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

HLS Therapeutics is loss making, we can't compare its value to the US Healthcare industry average.

HLS Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for HLS Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

HLS Therapeutics is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is HLS Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

27.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

HLS Therapeutics's revenue is expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).

HLS Therapeutics's earnings are expected to grow significantly at over 20% yearly.

HLS Therapeutics's revenue growth is expected to exceed the United States of America market average.

HLS Therapeutics's earnings growth is expected to exceed the United States of America market average.

HLS Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if HLS Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has HLS Therapeutics performed over the past 5 years?

-30.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

HLS Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare HLS Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare HLS Therapeutics's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if HLS Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if HLS Therapeutics has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if HLS Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is HLS Therapeutics's financial position?


Financial Position Analysis

HLS Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

HLS Therapeutics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

HLS Therapeutics's level of debt (50.1%) compared to net worth is high (greater than 40%).

Unable to establish if HLS Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making HLS Therapeutics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making HLS Therapeutics has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -31.3% per year.


Next Steps

Dividend

What is HLS Therapeutics's current dividend yield, its reliability and sustainability?

1.37%

Current Dividend Yield


Upcoming Dividend Payment

Purchase HLS Therapeutics before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

HLS Therapeutics's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

HLS Therapeutics's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

It is too early to tell whether HLS Therapeutics has stable dividend payments.

HLS Therapeutics only just started paying a dividend, it is too early to tell if payments are increasing.


Current Payout to Shareholders

The company is paying a dividend however it is incurring a loss.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of HLS Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Greg Gubitz (62yo)

5.3yrs

Tenure

US$1,222,437

Compensation

Mr. Gregory David Gubitz, also known as Greg, B.A., LL.B, is Co-Founder of HLS Therapeutics Inc. and serves as its Chief Executive Officer and Director. Mr. Gubitz serves as an Executive Officer for MDS, I ...


CEO Compensation Analysis

Greg's remuneration is lower than average for companies of similar size in United States of America.

Greg's compensation has increased whilst company is loss making.


Management Age and Tenure

1.7yrs

Average Tenure

58yo

Average Age

The average tenure for the HLS Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.1yrs

Average Tenure

61yo

Average Age

The tenure for the HLS Therapeutics board of directors is about average.


Insider Trading

More shares have been bought than sold by HLS Therapeutics individual insiders in the past 3 months.


Recent Insider Transactions

SellUS$6,866,02406 Sep 19
OrbiMed Advisors, L.L.C.
EntityCompany
Shares673,145
Max PriceUS$10.20
BuyUS$5,07530 Aug 19
Ryan Lennox
EntityIndividual
Role
Chief Legal Officer
General Counsel & Corporate Secretary
Shares500
Max PriceUS$10.15
BuyUS$32,82720 Aug 19
Gregory Gubitz
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares3,000
Max PriceUS$10.94
BuyUS$53,77919 Aug 19
Gilbert Godin
EntityIndividual
Role
President
President & COO
Shares5,000
Max PriceUS$10.76
BuyUS$210,68316 Aug 19
William Wells
EntityIndividual
Role
Chairman of the Board
Co-Founder & Executive Chairman
Shares20,000
Max PriceUS$10.53
BuyUS$117,05214 Aug 19
William Wells
EntityIndividual
Role
Chairman of the Board
Co-Founder & Executive Chairman
Shares10,000
Max PriceUS$11.71
SellUS$2,333,47607 Jun 19
William Wells
EntityIndividual
Role
Chairman of the Board
Co-Founder & Executive Chairman
Shares200,000
Max PriceUS$11.67

Ownership Breakdown


Management Team

  • Greg Gubitz (62yo)

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: US$1.22m
  • Bill Wells (58yo)

    Co-Founder & Executive Chairman

    • Tenure: 5.3yrs
    • Compensation: US$907.12k
  • Gilbert Godin (60yo)

    President & COO

    • Tenure: 5.4yrs
    • Compensation: US$1.20m
  • Sanjiv Sharma (63yo)

    Chief Commercial Officer

    • Tenure: 1yrs
    • Compensation: US$658.52k
  • Hemanth Varghese (43yo)

    Head of Corporate Strategy & Business Development

    • Tenure: 2yrs
  • Tim Hendrickson (47yo)

    Chief Financial Officer

    • Tenure: 1yrs
    • Compensation: US$481.59k
  • Ryan Lennox (38yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.3yrs

Board Members

  • Greg Gubitz (62yo)

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: US$1.22m
  • Laura Brege (61yo)

    Independent Director

    • Tenure: 0.7yrs
  • J. Lanthier (78yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$194.95k
  • Bill Wells (58yo)

    Co-Founder & Executive Chairman

    • Tenure: 5.3yrs
    • Compensation: US$907.12k
  • Don DeGolyer (57yo)

    Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$54.15k
  • Yvon Bastien (72yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$178.92k
  • Rodney Hill (51yo)

    Independent Director

    • Tenure: 4.5yrs
    • Compensation: US$54.82k

Company Information

HLS Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HLS Therapeutics Inc.
  • Ticker: HLTR.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: CA$446.668m
  • Listing Market Cap: CA$336.552m
  • Shares outstanding: 30.74m
  • Website: https://www.hlstherapeutics.com

Number of Employees


Location

  • HLS Therapeutics Inc.
  • 10 Carlson Court
  • Suite 701
  • Toronto
  • Ontario
  • M9W 6L2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HLSTSX (The Toronto Stock Exchange)YesCommon SharesCACADMar 2018
HLTR.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2018

Biography

HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It markets Cl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/24 00:27
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.